Novo Nordisk has filed for regulatory approval of faster-acting insulin aspart for the treatment of type 1 and 2 diabetes in the EU and the US.
Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes
The filing of faster-acting insulin aspart is based on the results from the “onset” clinical trial programme which involved around 2 100 people with type 1 and 2 diabetes.
In the onset programme, people treated with faster-acting insulin aspart achieved improvements in postprandial control versus NovoLog (marketed as NovoRapid outside the US) and an HbA1creduction on par with NovoLog.
Source: Novo Nordisk